Preview

Медицинский Совет

Расширенный поиск

Что мы знаем сегодня о Lactobacillus reuteri?

https://doi.org/10.21518/2079-701X-2018-2-163-169

Полный текст:

Аннотация

Современные молекулярно-генетические методы исследования, появившиеся в XXI в., полностью перевернули наши представления не только о микромире, но и о его влиянии на жизнь и здоровье макроорганизма. Идентификация кишечных бактерий и особенности их разных штаммов все больше расширяют наше понимание механизмов их влияния на соматическое и психическое здоровье человека. На сегодняшний день наиболее изученными являются различные штаммы лактобацилл. Известно, что род Lactobacillus включает примерно 90 видов с широким спектром биохимических и физиологических свойств. Одним из уникальных микроорганизмов семейства Lactobacillaceae является Lactobacillus reuteri, имеющая штаммы с разным механизмом действия. На сегодняшний день спектр возможностей использования разных штаммов Lactobacillus reuteri очень широкий. В данной статье рассмотрены клинические эффекты, связанные со штаммоспецифичностью Lactobacillus reuteri.

Об авторах

И. Н. Захарова
Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия

Доктор медицинских наук, профессор



И. В. Бережная
Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия

Кандидат медицинских наук



Н. Г. Сугян
Российская медицинская академия непрерывного профессионального образования Минздрава России; Детская городская поликлиника №133 Департамента здравоохранения г. Москвы
Россия

Кандидат медицинских наук



Т. Н. Санникова
Химкинская центральная клиническая больница
Россия

Кандидат медицинских наук



А. Е. Кучина
Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия


Ю. О. Сазанова
Российская медицинская академия непрерывного профессионального образования Минздрава России
Россия


Список литературы

1. Food and Agricultural Organization of the United Nations and World Health Organization. Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. Food and Agricultural Organization of the United Nations, 2002. [online], ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.

2. Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clinical Microbiology Reviews, 2003, 16(4): 658-720.

3. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol., 2014 June, 11(8). doi: 10.1038/nrgastro.2014.66.

4. Мечников И.И. Этюды о природе человека. 4-е изд. М., 1913.

5. Valeur N, Engel P et al. Colonization and immuno-modulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol, 2004, 70: 1176-1181.

6. Tubelius P, Stan V, Zachrisson A. Increasing workplace healthiness with the probiotic Lactobacillus reuteri: A randomized, doubleblind placebo-controlled study. Environmental Health, 2005, 4: 25. Free access available at htpp://www.ehjournal.net/content/4/1/25.

7. Sanders ME. New York Academy of Sciences, “Science & The City” podcast about probiotics. Free podcast (“More Than A Yogurt Cup”) available at NYAS website and on iTunes (search “Science & The City”), 2010.

8. Sanders ME. Considerations for Use of Probiotic Bacteria to Modulate Human Health. J Nutr, 2000, 130: 3845-3905.

9. Wold AE. Immune effects of probiotics. Scand J Nutr, 2001, 45: 76-85.

10. Christensen HR et al. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol, 2002, 168: 171-178.

11. Nagata S, Asahara T, Ohta T, Yamada T, Kondo S, Bian L, Wang C, Yamashiro Y, Nomoto K. British Journal of Nutrition, 2011, 106: 549-556 doi: 10.1017/S000711451100064X.

12. King S, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. Br J Nutr, 2014, 112: 41-54.

13. Shida K, Sato T, Iizuka R, Hoshi R, Watanabe O, Igarashi T, Miyazaki K, Nanno M, Ishikawa F. Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers. European Journal of Nutrition, 2017 February, 56(Issue 1): 45-53.

14. Klebanoff SJ, Coombs RW. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J. Exp. Med., 1991, 174(1): 289-292.

15. Michetti P, Dorta G, Wiesel PH et al. Effect of whey based culture supernatant of Lactobacil lus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion, 1999, 60: 203.

16. Савино Ф., Захаровa И.Н. Диагностика и лечение младенческих кишечных колик: мнение экcпертов ESPGHAN. Consilium Medicum. Педиатрия (Прил.)., 2016, 2: 10-17.

17. Silva M, Jacobus NV, Deneke C, Gorbach SL. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother, 1987, 31: 1231.

18. Forestier C, De Champs C, Vatoux C, Joly B. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adhe rence to intestinal cells and antimicrobial properties. Res Microbiol, 2001, 152: 167-173.

19. Sarra PG, Dellaglio F, Bottazzi V. Genetic heterogeneity among Lactobacillus acidophilus strains. Syst. Appl. Microbiol., 1985, 6: 86-99.

20. Kandler O et al. Lactobacillus reuteri sp. nov. a new species of heterofermentative lactobacilli. Zbl Bakt Hyg Abt Orig, 1980, 1: 264-269.

21. Reuter G. The Lactobacillus and Bifidobacterium Microflora of the Human Intestine: Composition and Succession. Curr Issues Intest Microbiol, 2001, 2: 43-53.

22. Schuller S. How Lactobacillus reuteri protects against enteropathogenic E. coli infection in the human gut. March 4, 2016. https://quadram.ac.uk/how-probiotic-protects-against-pathogen-infection-in-the-gut/

23. Di Nardo G, Oliva S, Menichella A, Pistelli R, De Biase RV, Patriarchi F, Cucchiara S, Stronati L. Lactobacillus reuteri ATCC55730 in Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2014 Jan, 58(1): 81–86. doi: 10.1097/MPG.0000000000000187, PMID: 24121143 Issn Print: 0277-2116 Publication Date: 2014/01/01.

24. Jalasvuori H, Haukioja A, Tenovuo J. Probiotic Lactobacillus reuteri strains ATCC PTA 5289 and ATCC 55730 differ in their cariogenic properties in vitro. Archives of Oral Biology, 2012, 57(12): 1633-8.

25. Gruner D, Paris S, Schwendicke F. Probiotics for managing caries and periodontitis: systematic review and meta-analysis. J Dent, 2016, 48: 16-25.

26. Sinkiewicz G et al. Influence of dietary supplementation with Lactobacillus reuteri on the oral flora of healthy subjects. Swed Dent J., 2010, 34: 197–206.

27. Ericson D, Hamberg K, Bratthall G, SinkiewiczEnggren G, Ljunggren L. Salivary IgA response to probiotic bacteria and mutans streptococci after the use of chewing gum containing Lactobacillus reuteri. Pathog Dis, 2013, 68: 82-87.

28. Francavilla R, Castellaneta S, Lionetti E, Miniello VL. Inhibition of Helicobacter pylori Infection in Humans by Lactobacillus reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study. Helicobacter, 2008 May, 13(2): 127-34. doi: 10.1111/j.1523-5378.2008.00593.x.

29. Ojetti V, Bruno G, Ainora ME, Gigante G, Rizzo G, Roccarina D, Gasbarrini A. Impact of Lactobacillus reuteri Supplementation on AntiHelicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterology Research and Practice, 2012, 2012: ID 740381. doi: 10.1155/2012/740381.

30. Бордин Д.С., Войнован И.Н., Хомерики С.Г., Янова О.Б., Ким В.А., Быстровская Е.В., Шишин К.В. Эффективность и безопасность Lactobacillus reuteri DSMZ17648 у инфицированных Helicobacter pylori. Лечащий врач, 2016, 05.

31. Mehling H, Busjahn A. Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans. Nutrients, 2013, 5(8): 3062-3073.

32. Плотникова Е.Ю., Грачева Т.Ю. Роль пробиотиков в лечении Hр-ассоциированных заболеваний. Медицинский совет, 2017, 5: 80-84.

33. Montesi A et al. Molecular and microbiological analysis of caecal microbiota in rats fed with diets supplemented either with prebiotics or probiotics. Int J Food Microbiol, 2005, 98(3): 281-289.

34. Jones ML et al. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. The British journal of nutrition, 2011 November, 107(10): 1505-1513.

35. Martinez RCR, Franceschini SA, Patta MC, Quintana SM, Gomes BC, De Martinis ECP, Reid G. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebocontrolled trial. Canadian Journal of Microbiology, 2009, 55(2): 133-138. https: //doi.org/10.1139/W08-102.

36. Casas IA, Dobrogosz WJ. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microbial Ecol Health Dis, 2000, 12(4): 247-285.

37. Афонюшкин В.Н., Филипенко М.Л., Ширшова А.Н., Маслов О. Г. Механизмы биологической активности системы Lactobacillus reuteri – реутерин. Проблемы. Суждения, 2013, 4: 70-75.

38. Chung TC, Axelsson L, Lindgren SE, Dobrogosz WJ. Studies in vitro9. Reuterin synthesis of Lactobacillus reuteri. MicrobEcol Health Dis, 1989, 2: 137-140.

39. Axelsson LT, Chung TC, Dobrogosz WJ, Lindgren SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. MicrobEcol Health Dis, 1989, 2: 131-136.

40. Hidetoshim et al. Comparative genome analysis of Lactobacillus reuteri and Lactobacillus fermentum reveal a genomic island for reuterin and cobalamin production. Published online 16.05.2008.

41. Kiňová HS, Bilková A. Isolation and identification of new lactobacilli from goatling stomach and investigation of reuterin production in Lactobacillus reuteri strains. Folia Microbiologica, 2013 January, 58(Issue 1): 33-38.

42. Höltzel A et al. The First Low Molecular Weight Antibiotic from Lactic Acid Bacteria: Reutericyclin, a New Tetramic Acid. Angew Chem Int Ed Engl. 2000.

43. Spinler JK, Sontakke A, Hollister E, Venable SF, Oh PL. From prediction to function using evolutionary genomics: Human-specific ecotypes of Lactobacillus reuterihave diverse probiotic functions. Genome Biology and Evolution, 2014 June, 19, doi: 10.1093/gbe/evu137.

44. Thomas CM, Hong T, van Pijkeren JP, Hemarajata P, Trinh DV, Hu W, Britton RA, Kalkum M, Versalovic J. Histamine Derived from Probiotic Lactobacillus reuteri Suppresses TNF via Modulation of PKA and ERK Signaling. PLoS ONE, 2012, 7(2): e31951. doi: 10.1371/journal.pone.0031951|www.plosone.org.

45. Lin YP, Thibodeaux CH, Pena JA, Ferry GD, Versalovic J. Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. Inflamm Bowel Dis, 2008, 14: 1068-1083.

46. Iyer C, Kosters A, Sethi G, Kunnumakkara AB, Aggarwal BB et al. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. Cell Microbiol, 2008, 10: 1442-1452.

47. Castiblanco GA, Yucel-Lindberg T, Roos S, Twetman S. Effect of Lactobacillus reuteri on Cell Viability and PGE2 Production in Human Gingival Fibroblasts. Probiotics and Antimicrobial Proteins, 2017, 9(Issue 3): 278-283.

48. Ohlsson C et al. Probiotics protect mice from ovariectomy-induced cortical bone loss. PLoS One, 2014.

49. Abrahamsson TR, Jakobsson T, Björkstén B, Oldaeus G, Jenmalm MC. No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy. Pediatric Allergy and Immunology, 2013 September, 24(Issue 6): 556-561.

50. Cirillo A, Boccia E, Cirillo Ar, Scotto G, Maiella D, De Crescenzo G, Leone G, Grimaldi S, Cirillo Ag. Effectiveness of Lactobacillus reuteri in patients with atopic dermatitis and cow milk intolerance. Preliminary study. Presented at the Italian Society for Clinical Allergy and Immunology (SIAIC) Congress, Rome, Italy, 4-7 May 2005. Abstract P-08.

51. Kheirkhah D, Sharif MR, Rezaei MH, Ardakani AT. Relationship between type of nutrition and infantile colic. International Journal of Medical Research & Health Sciences, 2016, 5(12): 261-264.

52. Pärtty A, Kalliomäki M, Endo A, Salminen S, Isolauri E. Compositional Development of Bifidobacterium and Lactobacillus Microbiota Is Linked with Crying and Fussing in Early Infancy. PLoS One, 2012, 7(3): e32495.

53. De Weerth C, Fuentes S, Puylaert P, De Vos WM. Intestinal Microbiota of Infants With Colic: Development and Specific Signatures. Pediatrics, 2013, 131: e550. Originally published online January 14, 2013, DOI: 10.1542/peds.2012-1449.

54. Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr, 1999, 69: 1035S-1045S.

55. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infantformula on infections in child care centers: comparison of twoprobiotic agents. Pediatrics, 2005, 115: 5-9.

56. Kalliomäki M, Salminen S, Arvilommi H, Kero P, KoskinenP, Isolauri E. Probiotics in the primary prevention of atopicdisease: a randomised placebo-controlled trial. Lancet, 2001, 357: 1076-1079.

57. Roseth AG, Fagerhol MK, Aadland E et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand. J. Gastroenterol., 1992, 27: 793-798.

58. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium<111<labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol., 1999, 34: 50-54.

59. Татьянина О.Ф., Потапов А.С., Намазова Л.С., Цимбалова Е.Г., Кучеренко А.Г., Лохматов М.М. Фекальный кальпротектин в неинвазивной диагностике воспалительных заболеваний кишечника у детей. Педиатрическая фармакология, 2008, 5(3): 46-51.

60. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr, 2013, 162: 257–6.

61. Sung V, Hiscock H, Tang M, Mensah FK, Monica L, Satzkeresearch C, Heine RG, Stock A, Barrprofessor RG, Wake M. Treating infant colic with the probiotic Lactobacillus reuteri: doubleblind, placebo controlled randomised trial. BMJ, 2014, 348: g2107. doi: 10.1136/bmj.g2107 (Published April 2014).

62. Indrio F, Mentula S, Partty A, Tancredi D. Lactobacillus reuteri to Treat Infant Colic: A Metaanalysis. Pediatrics, 2018 Jan, 141(1). Department of Pediatrics, University of California Davis Health System, Sacramento, California.

63. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther, 2012 Feb, 35(3): 327-334. doi: 10.1111/j.1365-2036.2011.04939.x. Epub 2011 Dec 8.


Просмотров: 132


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)